Anthracyclines

"Anthracyclines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.

Descriptor ID	D018943
MeSH Number(s)	D02.455.426.559.847.562.050 D04.615.562.050 D09.408.051.059
Concept/Terms	Anthracyclines Anthracyclines

Below are MeSH descriptors whose meaning is more general than "Anthracyclines".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Polycyclic Aromatic Hydrocarbons [D02.455.426.559.847]
Naphthacenes [D02.455.426.559.847.562]
Anthracyclines [D02.455.426.559.847.562.050]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Naphthacenes [D04.615.562]
Anthracyclines [D04.615.562.050]
Carbohydrates [D09]
Glycosides [D09.408]
Aminoglycosides [D09.408.051]
Anthracyclines [D09.408.051.059]

Below are MeSH descriptors whose meaning is related to "Anthracyclines".

Below are MeSH descriptors whose meaning is more specific than "Anthracyclines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Anthracyclines" by people in this website by year, and whether "Anthracyclines" was a major or minor topic of these publications.

Bar chart showing 8 publications over 8 distinct years, with a maximum of 1 publications in 2004 and 2007 and 2009 and 2012 and 2020 and 2021 and 2023 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2007	1	0	1
2009	1	0	1
2012	1	0	1
2020	1	0	1
2021	0	1	1
2023	0	1	1
2024	0	1	1

Below are the most recent publications written about "Anthracyclines" by people in Profiles.

Park YM, Jung W, Yeo Y, Park SH, Fradley MG, Malapati SJ, Tarun T, Raj V, Lee HS, Naqvi TZ, Henry-Tillman RS, Mehta JL, Schootman M, Amick BC, Han K, Shin DW. Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors. BMC Med. 2024 02 28; 22(1):88.

View in: PubMed
Huang X, Fan XY, Cheng Q, Zhang J, Sun J, Tang QY, Deng YB, Bi XJ. Intrinsic Wave Velocity Propagation: A Novel Parameter for Assessing the Effect of Anthracycline Chemotherapy Agents on Cardiac Diastolic Function in Breast Cancer Patients. Curr Med Sci. 2023 Dec; 43(6):1229-1237.

View in: PubMed
Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia. 2021 10; 35(10):2994-2997.

View in: PubMed
Sapkota Y, Qin N, Ehrhardt MJ, Wang Z, Chen Y, Wilson CL, Estepp J, Rai P, Hankins JS, Burridge PW, Jefferies JL, Zhang J, Hudson MM, Robison LL, Armstrong GT, Mulrooney DA, Yasui Y. Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry. Cancer Res. 2021 05 01; 81(9):2556-2565.

View in: PubMed
Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012 Jun 20; 30(18):2232-9.

View in: PubMed
Freilich M, Stub D, Esmore D, Negri J, Salamonsen R, Bergin P, Leet A, Richardson M, Taylor A, Woodard J, Kaye D, Rosenfeldt F. Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device. J Heart Lung Transplant. 2009 Jan; 28(1):101-3.

View in: PubMed
Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007 Sep 01; 25(25):3808-15.

View in: PubMed
Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol. 2004 Jan 15; 67(2):353-64.

View in: PubMed

People

Explore

Similar Concepts

Top Journals